07.28.15
Boehringer Ingelheim and Hanmi Pharmaceutical Co. entered an exclusive license and collaboration agreement for the development and commercialization of HM61713, a next-gen EGFR targeted therapy for the treatment lung cancer. HM61713 is currently in Phase II development in patients with non-small cell lung cancer (NSCLC) with T790M mutations who have developed resistance to previous EGFR targeting agents. A Phase III program will be initiated in 2016.
Hanmi will receive an initial payment of $50 million and is entitled to potential milestones of $680 million plus royalties on future sales.
Dr. Jörg Barth, corporate senior vice president, Therapy Area Head Oncology, Boehringer Ingelheim said, "This exclusive license agreement with Hanmi Pharmaceutical is a significant step towards our vision of providing a wide-range of lung cancer treatment options as we better understand the underlying drivers of this devastating disease. The in-licensing of a 3rd generation EGFR agent bolsters our existing lung cancer portfolio and reiterates our commitment towards improving the lives of people with cancer through innovation and tailored treatment options."
Dr. Jeewoong Son, chief medical officer of Hanmi Pharmaceutical said, "We are excited at the potential this license agreement with Boehringer Ingelheim will bring to the successful development of HM61713 and the possibilities this will offer to lung cancer patients. Boehringer has significant expertise in the field of lung cancer, specifically in EGFR mutated disease. With Boehringer's strong pipeline demonstrating its long-term commitment to successful development of cancer treatments, we are confident we have found the right partner to make the potential of HM61713 a reality."
Hanmi will receive an initial payment of $50 million and is entitled to potential milestones of $680 million plus royalties on future sales.
Dr. Jörg Barth, corporate senior vice president, Therapy Area Head Oncology, Boehringer Ingelheim said, "This exclusive license agreement with Hanmi Pharmaceutical is a significant step towards our vision of providing a wide-range of lung cancer treatment options as we better understand the underlying drivers of this devastating disease. The in-licensing of a 3rd generation EGFR agent bolsters our existing lung cancer portfolio and reiterates our commitment towards improving the lives of people with cancer through innovation and tailored treatment options."
Dr. Jeewoong Son, chief medical officer of Hanmi Pharmaceutical said, "We are excited at the potential this license agreement with Boehringer Ingelheim will bring to the successful development of HM61713 and the possibilities this will offer to lung cancer patients. Boehringer has significant expertise in the field of lung cancer, specifically in EGFR mutated disease. With Boehringer's strong pipeline demonstrating its long-term commitment to successful development of cancer treatments, we are confident we have found the right partner to make the potential of HM61713 a reality."